Nuvalent Inc. (NASDAQ:NUVL) is one of the best high short interest stocks with huge upside potential. On June 24, Nuvalent ...

New data indicate a targeted drug from Nuvalent could help patients with a rare lung cancer for whom other drugs stopped ...

Onco360®, the nation’s leading independent specialty pharmacy, has added Augtyro™ (repotrectinib) manufactured by Bristol ...

Brain metastases are common in ROS1-positive NSCLC, particularly after disease progression. Among 56% with measurable brain lesions, zidesamtinib mounted a 48% intracranial ORR, including 20% ...

New study results position Nuvalent to bring forward what it claims is a differentiated treatment for ROS1-positive lung ...

Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; ...

Nuvalent's promising trial results for zidesamtinib show a 44%-51% response rate in ROS1-positive lung cancer. Read more here ...

Cambridge, Massachusetts-based Nuvalent has reported the results of its phase 1/2 ARROS-1 trial of zidesamtinib in previously ...

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the ...

Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 best healthcare penny stocks to buy according to analysts. JMP Securities ...